The combination of Ipamorelin and CJC-1295 Without DAC represents a dual-pathway peptide complex widely investigated in endocrine and cellular biology models. By pairing a highly selective growth hormone secretagogue receptor agonist with a modified growth hormone-releasing hormone analog, this co-formulation allows researchers to evaluate amplified, physiological growth hormone pulses and downstream IGF-1 expression without extended receptor desensitization.
The combination of Ipamorelin and CJC-1295 Without DAC represents a dual-pathway peptide complex widely investigated in endocrine and cellular biology models. By pairing a highly selective growth hormone secretagogue receptor agonist with a modified growth hormone-releasing hormone analog, this co-formulation allows researchers to evaluate amplified, physiological growth hormone pulses and downstream IGF-1 expression without extended receptor desensitization.
In physiological system models, growth hormone (GH) secretion from anterior pituitary somatotrophs is regulated by two distinct, complementary signaling cascades. The first is initiated by Growth Hormone-Releasing Hormone (GHRH), which binds to the transmembrane GHRH receptor (GHRHR) and triggers intracellular cyclic adenosine monophosphate (cAMP) accumulation. The second pathway relies on the Growth Hormone Secretagogue Receptor (GHS-R1a), activated naturally by ghrelin or synthetically by selective peptidomimetics, which mobilizes intracellular calcium (Ca2+) via the phospholipase C (PLC) pathway.
When co-administered in preclinical models, ipamorelin cjc 1295 without dac targets both signal transduction pathways simultaneously. In vitro somatotroph cultures demonstrate that concurrent activation of GHRHR and GHS-R1a produces a supra-additive or synergistic release of growth hormone rather than a merely additive response. This dual-action dynamic mimics natural physiological pulsatility while enabling laboratory investigators to observe heightened downstream signaling cascades without requiring supra-physiological individual peptide concentrations.
Researchers frequently select this dual formulation to investigate cellular repair mechanisms, protein translation dynamics, and metabolic substrate partitioning. By leveraging two independent receptor targets, studies can achieve robust GH signaling while minimizing receptor downregulation, a common limitation observed with single-agent high-dose secretagogue protocols.
CJC-1295 Without DAC, also designated in literature as Modified GRF 1-29 (Growth Hormone-Releasing Factor), is a 29-amino-acid synthetic peptide analog of native GHRH(1-29). Native GHRH is rapidly cleaved in biological matrices by the enzyme dipeptidyl peptidase IV (DPP-IV), which targets the Ala2 position. To enhance enzymatic resistance and extend the operational plasma half-life in laboratory models, Modified GRF 1-29 incorporates four key amino acid substitutions: D-Ala2, Gln8, Ala15, and Leu27.
These structural modifications protect the primary cleavage site while preserving high binding affinity for the GHRH receptor. Unlike versions containing the Drug Affinity Complex (DAC), which covalently binds serum albumin to extend circulating half-life to several days, CJC-1295 Without DAC exhibits a clearance profile measured in minutes to hours. This shorter biological half-life allows researchers to induce discrete, pulsatile surges of endogenous GH that closely mimic normal mammalian physiology.
As a GHRH analog, CJC-1295 Without DAC is studied primarily for its role as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. For investigators comparing different GHRH derivatives, sourcing validated compounds from our comprehensive catalogue of growth hormone releasing peptides ensures consistent structural integrity across experimental trials.
Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Recognized as one of the most selective growth hormone secretagogues developed, ipamorelin peptide binds specifically to the GHS-R1a receptor with high affinity. Unlike earlier generation ghrelin mimetics such as GHRP-6 or GHRP-2, Ipamorelin does not induce significant elevations in plasma cortisol, adrenocorticotropic hormone (ACTH), or prolactin levels in preclinical assays.
This extreme receptor selectivity is attributed to its unique structural configuration, incorporating non-canonical amino acids such as alpha-aminoisobutyric acid (Aib) and D-2-naphthylalanine (D-2-Nal). In vitro radieligand binding assays demonstrate that Ipamorelin stimulates growth hormone release with potency comparable to GHRP-6, but without activating secondary neuroendocrine stress pathways.
In laboratory models evaluating metabolic rate, body composition, and tissue regeneration, Ipamorelin provides a clean pharmacological probe. Researchers can isolate the physiological effects of GHS-R1a activation without confounding variables introduced by stress hormone co-stimulation.
The primary rationale for investigating ipamorelin cjc 1295 without dac as a unified research complex lies in its pharmacokinetic alignment. CJC-1295 Without DAC exhibits an elimination half-life of approximately 30 minutes in rodent models, while Ipamorelin possesses a half-life of approximately 2 hours. When combined in vitro or in animal models, both agents peak almost synchronously, creating a coordinated surge in intracellular cAMP and Ca2+ within pituitary somatotrophs.
This temporal coordination generates a clean, pulsatile release of GH into circulation. Natural mammalian pituitary function relies on discrete secretory pulses rather than continuous elevated exposure. Continuous exposure to GHRH or GHRP agonists can lead to receptor internalization, desensitization, and blunted downstream expression. By utilizing the non-DAC variant of CJC-1295 alongside Ipamorelin, preclinical protocols preserve the natural episodic signaling pattern essential for long-term cellular responsiveness.
Downstream from the pituitary axis, this pulsatile GH elevation stimulates hepatic synthesis and secretion of Insulin-like Growth Factor 1 (IGF-1). IGF-1 acts as the primary mediator of GH-driven cellular proliferation, satellite cell activation in skeletal muscle, and extracellular matrix remodeling in connective tissues.
When designing preclinical growth factor studies, selecting the appropriate secretagogue class is critical for protocol validity. CJC-1295 Without DAC is often evaluated alongside alternative GHRH analogs such as CJC-1295 DAC and Sermorelin, as well as alternative ghrelin receptor agonists like GHRP-2. While CJC-1295 DAC incorporates a maleimidopropionic acid linker to bind plasma proteins and prolong activity for over a week, CJC-1295 Without DAC rapidly clears, making it ideal for studies investigating short-burst, pulsatile GH mechanics.
Sermorelin represents an earlier-generation GHRH(1-29) fragment that lacks the four stabilizing amino acid substitutions present in Modified GRF 1-29. Consequently, Sermorelin exhibits a significantly shorter plasma half-life (under 12 minutes) and greater susceptibility to enzymatic degradation by DPP-IV. In comparative in vitro assays, Modified GRF 1-29 demonstrates superior stability and total GH area-under-the-curve (AUC) relative to unsubstituted Sermorelin.
Among GHRP agonists, Ipamorelin offers distinct advantages over GHRP-2 and GHRP-6 due to its minimal impact on baseline cortisol and prolactin. While GHRP-2 provides potent GH release, it routinely activates the hypothalamic-pituitary-adrenal (HPA) axis in animal models, elevating circulating glucocorticoids. Ipamorelin retains high secretagogue potency while completely sparing HPA axis cross-reactivity.
Preclinical literature demonstrates that the dual activation of GHRH and GHS-R1a pathways plays a profound role in extracellular matrix biosynthesis and tissue repair models. In rodent wound-healing and musculoskeletal injury models, co-stimulation of GH and IGF-1 accelerates fibroblast proliferation, collagen type I and III deposition, and localized neovascularization.
In skeletal muscle culture models, elevated IGF-1 concentrations downstream of ipamorelin cjc 1295 without dac administration upregulate muscle-specific transcription factors, including MyoD and myogenin. This pathway stimulates satellite cell activation and protein synthesis via the Akt/mTOR signaling cascade, providing key insights into muscle atrophy mitigation and cellular regeneration.
Additionally, research models focusing on metabolic regulation utilize this combination to evaluate lipid substrate utilization. Increased circulating growth hormone promotes lipolysis in adipocytes by upregulating hormone-sensitive lipase (HSL) activity, while preserving lean mass markers. Further mechanistic details on receptor kinetics can be reviewed in our expanded guide on peptidomimetic mechanisms.
To ensure analytical precision and reproducible experimental data, lyophilized peptide complexes must be handled according to strict physical chemistry protocols. Modern research peptides are supplied as sterile, freeze-dried powders in glass vials, stabilized with mannitol or matrix excipients. Upon receipt, un-reconstituted vials should be stored in a controlled freezer environment at -20°C or -80°C to prevent thermal degradation.
Reconstitution should be performed under aseptic conditions using a sterile diluent, typically standard bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline, depending on assay parameters. Diluent should be introduced gently along the internal glass wall of the vial to avoid mechanical shear stress, which can disrupt secondary and tertiary peptide structures. The vial should be gently swirled rather than vigorously vortexed.
Once reconstituted, peptide solutions undergo increased susceptibility to hydrolysis and oxidation. Working solutions must be refrigerated at 2°C to 8°C and utilized within 28 days. Avoid repeated freeze-thaw cycles, as crystal formation can induce peptide cleavage and aggregate formation, altering effective molar concentration during assays.
The reliability of preclinical data depends entirely on the purity and chemical identity of the research compounds used. Low-purity peptides containing truncated sequence fragments, unreacted coupling reagents, or heavy metal residues can introduce confounding variables, cellular toxicity, or off-target receptor interactions in biological assays.
PX1 Research enforces rigorous quality control standards across all product lines. Every batch of ipamorelin cjc 1295 without dac undergoes mandatory dual-stage testing: Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify chromatographic purity (>99%), and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify exact molecular mass and sequence identity.
Furthermore, biological assays involving cell culture or in vivo models require strict control over bacterial endotoxins. PX1 Research conducts Limulus Amebocyte Lysate (LAL) testing on every production lot to guarantee endotoxin levels remain well below established research thresholds (<0.01 EU/mg). Complete analytical documentation is publicly accessible via our analytical testing protocols library.
Securing consistent, verified research peptides is critical for academic laboratories, biotechnology firms, and contract research organizations (CROs). PX1 Research operates state-of-the-art, GMP-compliant manufacturing facilities within the United States, utilizing ISO 17025 accredited analytical laboratories for independent verification.
Every standard and custom formulation shipped from our California and Arizona logistics hubs includes a lot-specific Certificate of Analysis (COA), documenting HPLC purity traces, mass spectrometry spectra, and endotoxin assay results. Orders processed Monday through Friday before cut-off times qualify for same-day dispatch, minimizing supply chain delays for active research projects.
For high-throughput screening projects, animal facility studies, or longitudinal institutional trials, PX1 Research offers flexible volume options and specialized account support. Explore our dedicated bulk research peptide procurement program to establish direct supply chains tailored to your facility's operational requirements.
What is the primary difference between CJC-1295 Without DAC and CJC-1295 With DAC?
CJC-1295 Without DAC (Modified GRF 1-29) lacks the Drug Affinity Complex (DAC) lysyl-linker. Consequently, it does not bind to serum albumin and exhibits a physiological plasma half-life of approximately 30 minutes, producing discrete GH pulses rather than continuous, multi-day GH elevation.
Why are Ipamorelin and CJC-1295 Without DAC co-evaluated in research models?
Ipamorelin targets the GHS-R1a (ghrelin) receptor to mobilize intracellular calcium, while CJC-1295 Without DAC targets the GHRH receptor to elevate cAMP. Co-activation of these complementary signaling pathways generates a synergistic, supra-additive surge in growth hormone secretion.
How should lyophilized Ipamorelin / CJC-1295 Without DAC be stored prior to reconstitution?
Lyophilized peptide vials should be stored at -20°C or -80°C in a dry, dark environment. Protected from moisture and heat, freeze-dried peptides remain stable for 24 months or longer.
What diluent is recommended for reconstituting peptide complexes for laboratory research?
Laboratory reconstitution typically utilizes sterile bacteriostatic water (containing 0.9% benzyl alcohol) to maintain microbial sterility for multi-use laboratory assays, or sterile 0.9% sodium chloride solution for immediate single-use in vitro protocols.
Does Ipamorelin cause cross-reactivity with cortisol or prolactin pathways?
Preclinical studies demonstrate that Ipamorelin exhibits exceptional receptor selectivity. Unlike older GHRP compounds (e.g., GHRP-2 or GHRP-6), Ipamorelin does not induce significant elevations in plasma ACTH, cortisol, or prolactin levels.
How does PX1 Research verify the purity of its research peptide lots?
Every lot manufactured by PX1 Research undergoes strict analytical testing at an ISO 17025 accredited facility, utilizing Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity assessment (>99%) and Mass Spectrometry (MS) for exact molecular weight confirmation.
What are the endotoxin thresholds for PX1 Research compounds?
All research peptides provided by PX1 Research undergo Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain below <0.01 EU/mg, preventing endotoxin-induced inflammation or cytotoxic effects in laboratory cell cultures.
Are PX1 Research compounds approved for human clinical use or patient therapy?
No. All products supplied by PX1 Research are strictly designated for laboratory research, in vitro testing, and preclinical animal research models. They are not for human or veterinary use, medical therapy, or clinical administration.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.